Viridian Therapeutics Inc. – Filings and Transcripts

NASDAQ: VRDN
Share price (5/22/26): $17.24
Market cap (5/22/26): $1.777 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Free writing prospectus

Free writing prospectus

Prospectus supplement for primary offering

Ownership Filter

Bellevue Group AG

Fairmount Healthcare Fund II L.P., Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC

Fairmount Funds Management LLC

Deep Track Capital, LP

Vanguard Group Inc

News Filter

Material Definitive Agreement, New Financial Obligation or Off-Balance Sheet Arrangement, Other Events, Financial Statements or Exhibits

Announces Positive Topline Results From Elegrobart Phase 3 REVEAL-2 Clinical Trial in Chronic Thyroid Eye Disease

Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Announces Positive Topline Results From Elegrobart Phase 3 REVEAL-1 Clinical Trial in Active Thyroid Eye Disease

Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Statement of eligibility as a trustee

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission